Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe Krupa who wrote (7549)	7/26/2001 11:55:37 AM
From: Joe Krupa	Read Replies (2) of 14101

In light of today's announcement from NICE on their ruliing against Celebrex and Vioxx, I thought I would re-post a particular Q&A recently added to the Dimethaid website. Note the bolded text. ********************************************************************************************* How is PENNSAID® available in the United Kingdom? PENNSAID® is available only as a prescription product in the United Kingdom. There are a number of marketing regulations which are peculiar to the U.K.: no unsolicited samples can be left with a physician and there are annual limits on the number of samples which can be given to each physician when requested. Consequently, all information and any samples for a patient must come directly from their physician. As direct to consumer advertising is prohibited in the U.K., there is no provision for direct communication between Provalis and patients. As is the case in North America, advertising to physicians is tightly regulated and all proposed marketing material must receive approval prior to their being disseminated to physicians. Q. In view of these restrictions, a patient in the U.K. will need to have their own physician write a prescription for PENNSAID® before they can use the product. A. To date, Provalis has reported wide acceptance of PENNSAID® by U.K. physicians, particularly upon learning that the active ingredient is diclofenac, a drug with an efficacy profile they know well. Their estimates of the physician rejection rate is about 1% and the reason most often cited is that they want to wait for U.K. experience with the product before prescribing it. In the interim, many are content to use the samples on themselves. With the British National Institute for Clinical Excellence (NICE) expected to provide their assessment on the use of COX-2 inhibitors sometime this month, we can expect Provalis to utilize this opportunity to expand the awareness of the benefits of PENNSAID®. dimethaid.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next